BRAF and melanoma: In another study two modulators of completely distinct signaling pathways, PAC-1 pro-caspase-3 activator and vemurafenib, inhibitor of BRAF oncogene, whose mutation is a common cause of melanoma, demonstrated strong therapeutic activity in prevention of resistance to MAPK inhibitors and tumor regrowth in preclinical melanoma models [12].